sensational.Profits are up almost 300% for the year and 165% for the quarter. They blew away the street expectations of 0.01 per share with 0.08. The forward pe is only 13.25 times next years guidance of 0.92 to 1.00. This company has a hot new gastro intestinal drug that shows a high efficacy result and will give them their 5th product in the market. The shorts are caught as usual when a company slams the earnings. Now is the time to buy not sell as the company will pick up some new analyst and could easily trade in a 30-40 pe range for the year. Even at 20 times future earnings yoou are looking at $20. I believe with the revenue growth and neww product development we are looking at a minimum target of 26 for 2013. Good luck to all.